The compound you described, **11-[2-[4-(2-aminoethyl)-1-piperazinyl]-1-oxoethyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one**, is a **benzodiazepine derivative**. It is not a commonly known compound, and there isn't readily available information on its specific properties or research significance.
However, based on its structure, it likely exhibits some pharmacological activity.
**Here's why:**
* **Benzodiazepines** are a class of psychoactive drugs known for their anxiolytic (anti-anxiety), sedative, hypnotic (sleep-inducing), anticonvulsant, and muscle relaxant properties. They work by enhancing the effects of the neurotransmitter GABA (gamma-aminobutyric acid) in the brain.
* **The specific modifications to the benzodiazepine core structure in this compound** (the 4-(2-aminoethyl)-1-piperazinyl group) could potentially influence its pharmacological activity. This side chain could affect the compound's:
* **Binding affinity to different GABA receptors**: There are several subtypes of GABA receptors in the brain. Modifying the benzodiazepine structure can alter its preference for specific subtypes, leading to different pharmacological effects.
* **Pharmacokinetic properties**: This side chain could affect how the compound is absorbed, distributed, metabolized, and excreted by the body, influencing its duration of action and potential side effects.
**Therefore, it's plausible that this compound could be of interest to researchers studying:**
* **Novel anxiolytics or sedatives**: The benzodiazepine core structure suggests potential for these activities, and the modifications could lead to compounds with improved efficacy or fewer side effects.
* **New therapeutic targets for neurological disorders**: Understanding how this compound interacts with GABA receptors and other brain targets could shed light on potential new treatments for epilepsy, anxiety disorders, and other neurological conditions.
**It's important to note:** Without more information about this specific compound, it's impossible to definitively determine its importance for research. Its properties and potential applications would need to be investigated through specific research studies.
| ID Source | ID |
|---|---|
| PubMed CID | 611101 |
| CHEMBL ID | 68771 |
| CHEBI ID | 93228 |
| SCHEMBL ID | 3667666 |
| Synonym |
|---|
| MLS001060775 |
| 11-(2-(4-(2-aminoethyl)piperazin-1-yl)acetyl)-5h-benzo[e]pyrido[3,2-b][1,4]diazepin-6(11h)-one |
| smr000486248 |
| 5,11-dihydro-11-[[4-(2-aminoethyl)-1-piperazinyl]acetyl]-6h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| CHEMBL68771 , |
| 11-[2-[4-(2-aminoethyl)piperazin-1-yl]acetyl]-5h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| 11-{2-[4-(2-amino-ethyl)-piperazin-1-yl]-acetyl}-5,11-dihydro-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one |
| bdbm50012339 |
| HMS2214G07 |
| HMS3340F04 |
| SCHEMBL3667666 |
| 5,11-dihydro-11-[(4-[2-aminoethyl]-1-piperazinyl)acetyl]-6h-pyrido[2,3-b][1,4]benzodiazepine-6-one |
| 6h-pyrido[2,3-b][1,4]benzodiazepin-6-one, 11-[[4-(2-aminoethyl)-1-piperazinyl]acetyl]-5,11-dihydro- |
| 11-([4-(2-aminoethyl)-1-piperazinyl]acetyl)-5,11-dihydro-6h-pyrido[2,3-b][1,4]benzodiazepin-6-one # |
| CHEBI:93228 |
| 11-[2-[4-(2-aminoethyl)-1-piperazinyl]-1-oxoethyl]-5h-pyrido[2,3-b][1,4]benzodiazepin-6-one |
| Q27164946 |
| Class | Description |
|---|---|
| benzodiazepine | A group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 0.7079 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 1.1900 | 0.0001 | 0.5797 | 10.0000 | AID141834 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 1.9700 | 0.0001 | 1.4833 | 9.1400 | AID141727 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | Ki | 2.8400 | 0.0001 | 0.6868 | 8.2600 | AID142012 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID142012 | Inhibition of binding of [3H]N-Methyl-scopolamine to muscarinic acetylcholine receptor M4 of rat heart NG108-15 cells | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Functionalized congener approach to muscarinic antagonists: analogues of pirenzepine. |
| AID142955 | Inhibition of binding of [3H]N-methylscopolamine to muscarinic acetylcholine receptor M2 of rat heart tissue membrane. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Functionalized congener approach to muscarinic antagonists: analogues of pirenzepine. |
| AID141727 | Inhibition of binding of [3H]N-methylscopolamine to muscarinic acetylcholine receptor M3 of transfected rat A9L cells. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Functionalized congener approach to muscarinic antagonists: analogues of pirenzepine. |
| AID141834 | Inhibition of binding of [3H]N-methylscopolamine to muscarinic acetylcholine receptor M1 of transfected rat A9L cells. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7 | Functionalized congener approach to muscarinic antagonists: analogues of pirenzepine. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.90) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||